Psychologists in Council Bluffs, IA Accepting Medicare
6 Psychologists found. Showing 1 - 6
 Jamie A Ryder, PHD Psychologist - Clinical Medicare: Accepting Medicare Assignments Practice Location: 810 Harmony St, Suite 302, Council Bluffs, IA 51503 Phone: 712-328-2609 Fax: 712-328-2609 |
 Dr. Gary Young Larsen, PH.D. Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 601 Willow Ave, Council Bluffs, IA 51501 Phone: 712-323-1728 Fax: 712-323-8888 |
Aubre Nicole Powers, MD Psychologist - Counseling Medicare: Not Enrolled in Medicare Practice Location: 500 Willow Ave Ste 402-407, Council Bluffs, IA 51503 Phone: 402-256-7913 |
Mary Ann M Strider, PH.D. Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 201 Ridge St, Suite # 105, Council Bluffs, IA 51503 Phone: 712-396-7500 |
Therese Korth Psychologist Medicare: Medicare Enrolled Practice Location: 147 15th Ave, Council Bluffs, IA 51503 Phone: 712-325-1331 |
Ms. Jennifer Lynn Edgington, M.S. BCBA, LBA, IBA Psychologist - Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 736 Valley View Dr Apt 7, Council Bluffs, IA 51503 Phone: 319-270-2854 |
News Archive
BioRx receives limited distribution rights from Baxter for AATD drug GLASSIA
BioRx, a specialty pharmacy company, has received limited distribution rights from Baxter International Inc. for a new drug, GLASSIA™ [Alpha 1-Proteinase Inhibitor (Human)], the first and only liquid, ready-to-use treatment for alpha-1 antitrypsin deficiency (AATD) in the United States. AATD is a genetic disorder that causes low levels of alpha 1-antitrypsin, resulting in emphysema. AATD is also referred to as "genetic" or "congenital" emphysema.
Transcept Pharmaceuticals to discuss the Complete Response Letter for Intermezzo NDA
Transcept Pharmaceuticals, Inc. today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet). As previously announced, the Complete Response Letter, received by Transcept on October 28, 2009, indicated that the FDA could not approve the NDA in its present form.
Government has overpaid private Medicare Advantage plans by billions of dollars
Incoming House Ways and Means Subcommittee on Health Chair Pete Stark (D-Calif.) on Thursday said that the federal government has overpaid private Medicare Advantage plans by billions of dollars, the San Francisco Chronicle reports.
First data from phase 3 study of investigational once-weekly DPP-4 inhibitor for type 2 diabetes presented by MSD
MSD, known as Merck & Co., Inc. (NYSE: MRK) in the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development programme for omarigliptin, MSD's investigational treatment for type 2 diabetes.
› Verified 9 days ago
Counselors
Pharmacists
Dentists
Clinical Social Workers
Occupational Therapists
Psychologists